ZHEJIANG YATAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.13 CNY | -1.57% |
|
+5.39% | -27.04% |
| Sales 2022 | 373M 51.54M 4.13B | Sales 2023 | 421M 58.05M 4.65B | Capitalization | 2.42B 334M 26.76B |
|---|---|---|---|---|---|
| Net income 2022 | -133M -18.36M -1.47B | Net income 2023 | -11M -1.52M -122M | EV / Sales 2022 | 7.59 x |
| Net Debt 2022 | 194M 26.8M 2.15B | Net cash position 2023 | 30.94M 4.27M 342M | EV / Sales 2023 | 5.68 x |
| P/E ratio 2022 |
-19.7
x | P/E ratio 2023 |
-215
x | Employees | 528 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.78% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.57% | ||
| 1 week | +5.39% | ||
| Current month | -11.58% | ||
| 1 month | -10.32% | ||
| 3 months | -19.54% | ||
| 6 months | -35.33% | ||
| Current year | -27.04% |
1 week
2.91
3.30
1 month
2.893.63
Current year
2.634.38
1 year
2.635.28
3 years
2.6310.20
5 years
2.6319.39
10 years
2.6322.15
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Ming Huang
CEO | Chief Executive Officer | 61 | 14/04/22 |
Jing Yang Xu
DFI | Director of Finance/CFO | 43 | 14/04/22 |
Wei Huang
BRD | Director/Board Member | 44 | 14/04/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hua Ying Zhou
BRD | Director/Board Member | 55 | 14/04/22 |
Ling Jie Song
CHM | Chairman | 35 | 14/04/22 |
Cai Fu
BRD | Director/Board Member | 56 | 03/07/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.13 | -1.57% | 12,484,560 |
| 25/04/24 | 3.18 | +1.27% | 13,978,880 |
| 24/04/24 | 3.14 | +2.61% | 9,395,130 |
| 23/04/24 | 3.06 | +2.34% | 6,861,500 |
| 22/04/24 | 2.99 | +0.67% | 5,227,200 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Zhejiang Yatai Pharmaceutical Co., Ltd. is a China-based company engaged in the manufacture and distribution of drugs. The Company's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Companyâs chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The Company distributes its products primarily in domestic markets and overseas markets.
Sector
Pharmaceuticals
Calendar
25/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.04% | 263M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002370 Stock
